Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
I-Mab Biopharma US Limited
Institut National de la Santé Et de la Recherche Médicale, France
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
Centre Leon Berard
MedImmune LLC
AstraZeneca
Jules Bordet Institute
Sheba Medical Center
Gustave Roussy, Cancer Campus, Grand Paris
M.D. Anderson Cancer Center
Syndax Pharmaceuticals
OHSU Knight Cancer Institute
University of Cincinnati
Duke University
MedImmune LLC
Institut Català d'Oncologia
Centre Leon Berard
Mirati Therapeutics Inc.
Eli Lilly and Company
AstraZeneca
King Faisal Specialist Hospital & Research Center
Grupo Español Multidisciplinar de Melanoma
MedImmune LLC